← AIDX
AIDX— 20/20 Biolabs, Inc.
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenues | $2.0M+16.7% | $1.8M |
| Cost of revenues | $1.4M+3.5% | $1.4M |
| Gross profit | $605K+67.8% | $360K |
| Sales, general and administrative | $3.3M-29.8% | $4.8M |
| Research and development | $593K-53.0% | $1.3M |
| Loss on impairment of fixed assets | $16K | — |
| Total operating expenses | $3.9M-34.8% | $6.0M |
| Operating loss | -$3.3M+41.3% | -$5.7M |
| Interest expense | -$156K-1135.2% | -$13K |
| Interest income | $21K-73.1% | $79K |
| Change in fair value of derivative liabilities | $8K | — |
| Loss on issuance of convertible note | -$281K | — |
| Other (expense) income, net | -$115-100.2% | $59K |
| Total other (expense) income | -$408K-424.4% | $126K |
| Net loss | -$3.7M+32.7% | -$5.6M |
| Basic net loss per common share (in Dollars per share) | -$0.76+34.5% | -$1.16 |
| Diluted net loss per common share (in Dollars per share) | -$0.76+34.5% | -$1.16 |
| Weighted-average common shares outstanding, basic (in Shares) | $4.9M+2.7% | $4.8M |
| Weighted-average common shares outstanding, diluted (in Shares) | $4.9M+2.7% | $4.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.